Uveitis Treatment Market Size, Trends, Share, Growth, and Regional Forecast, 2026 - 2033

Uveitis Treatment Market Share and Trends Analysis

The global uveitis treatment market size is estimated to reach US$ 905.8 million in 2026 and is projected to reach US$ 1,485.6 million by 2033, growing at a CAGR of 7.3% between 2026 and 2033.

The uveitis treatment focuses on controlling ocular inflammation to prevent vision loss while minimizing adverse effects. Key therapies include corticosteroids, cycloplegic agents, immunosuppressants, monoclonal antibodies, antibiotics, antivirals, antifungals, and analgesics. Corticosteroids, as the first-line therapy, dominate revenue due to wide usage across topical, systemic, and sustained-release formulations. Rising autoimmune disorders and infectious causes drive demand for antibiotics, particularly in developing countries, while idiopathic uveitis predominates in developed regions. Increasing prevalence, chronic disease management, and the need for targeted anti-inflammatory treatments are fueling steady market growth globally.

Key Industry Highlights

• Leading Region: North America dominates the global uveitis treatment market with 34.7% share, driven by advanced healthcare infrastructure, high disease awareness, and growing adoption of innovative therapies.
• Fastest-Growing Region: Asia Pacific is expected to expand rapidly with a CAGR of 9.1% over the forecast period, fueled by rising prevalence of uveitis and increasing healthcare investments.
• Leading Drug Class: Corticosteroids lead with 31.5% market share, supported by their role as first-line treatment, wide availability, and efficacy in controlling ocular inflammation.
• Leading Indication: Anterior uveitis is projected to remain dominant with 57.8% share, driven by high incidence among adults, early diagnosis, and established treatment protocols.
• Leading Disease Etiology: Non-infectious uveitis accounts for 74.8% of cases due to rising autoimmune disorders, better disease identification, and increasing clinical focus on non-infectious ocular inflammation.
• Leading Distribution Channel: Hospital pharmacies lead with 46.4% share, due to their ability to provide specialist medications, ensure adherence to treatment protocols, and serve high patient volumes.
• IL-6 inhibitors and JAK/STAT modulators are gaining traction, supported by clinical trial success and potential for targeted treatment in refractory cases.
• FDA and EMA approvals of novel therapies provide credibility, faster market entry, and encourage further R&D investments in uveitis treatments.
• Pipeline innovation for refractory and non-infectious uveitis continues to expand, driven by unmet medical needs and investment in next-generation therapeutic modalities.

Key Insights	Details
Global Uveitis Treatment Market Size (2026E)	US$ 905.8 million
Market Value Forecast (2033F)	US$ 1,485.6 million
Projected Growth (CAGR 2026 to 2033)	7.3%
Historical Market Growth (CAGR 2020 to 2025)	6.3%

Market Dynamics

Driver - Rising Prevalence of Uveitis and Eye Disorders Boosts Demand for Advanced Treatment Options Globally

Uveitis, the inflammation of the uveal tract—the vascular layer between the sclera (outer protective layer) and retina—cause severe visual impairment. The uveal tract comprises the posterior choroid, the middle ciliary body, and the anterior iris. A common complication is macular edema, characterized by fluid accumulation in the macula, the retina region responsible for sharp, central vision.

Globally, uveitis predominantly affects adults aged 20–50 years. Studies highlight that anterior uveitis, impacting the iris and ciliary body, accounts for 41%–60% of cases. Incidence is influenced by genetic factors, such as human leukocyte antigen–B27, environmental triggers like air pollution, and infection rates. In the U.S. and Europe, 27%–51% of cases are idiopathic, while 37%–49% are linked to systemic diseases, including axial spondyloarthritis.

Autoimmune disorders also play a significant role in uveitis, often affecting multiple organs. Intraocular inflammation, characteristic of autoimmune uveitis, is frequently associated with systemic autoimmune diseases, such as Behcet's disease, linked to Th17 cells. According to a 2023 review in Journal of Ophthalmic Inflammation and Infection, systemic autoimmune disease contributes to non-infectious uveitis in up to 33% of cases, while ocular surface disorders contribute in 53% of instances.

Additionally, complications such as glaucoma, the second leading cause of blindness worldwide, drive demand for effective treatments. With rising eye disorders globally, companies are developing novel drug candidates aligned with Good Manufacturing Practice (GMP) and regulatory guidelines, presenting significant market growth opportunities.

Restraints - Complex Sterile Formulations and Limited Healthcare Access Hinder Market Expansion

The global uveitis treatment market faces several challenges that constrain growth, primarily stemming from medication-related side effects and complex treatment protocols. Patients frequently report adverse effects such as ocular irritation, increased tearing, and other discomforts, which limit adherence and affect therapeutic outcomes. The relative scarcity of comprehensive clinical research on the long-term effectiveness of uveitis medications further complicates treatment decisions, posing significant challenges for healthcare practitioners and institutions.

Another critical restraint is the limited availability of first-line therapies. Uveitis medications often require specialized sterile formulations, necessitating adherence to stringent GMP guidelines. These formulations are highly sensitive to environmental pathogens and must be produced in controlled, highly protected facilities, making compliance with regulatory standards difficult for manufacturers.

Additionally, the market is hindered by inadequate healthcare infrastructure in several regions, particularly in developing countries. Limited awareness of ocular disorders, insufficient access to specialized ophthalmic care, and lack of comprehensive medical coverage exacerbate these challenges. These factors collectively restrict patient access to timely and effective treatments. As a result, despite ongoing research and innovation, these systemic, regulatory, and logistical barriers continue to restrain the global uveitis treatment market.

Opportunity - Growing Pipeline of Innovative Non-Infectious Uveitis Therapies

The global uveitis treatment market presents substantial opportunities driven by a growing pipeline of innovative therapies for non-infectious uveitis. Systemic and local treatments currently under clinical investigation include TYK2/JAK1 modulators and Interleukin-6 (IL-6) inhibitors, aimed at improving efficacy and safety profiles for patients with limited options.

In January 2024, Tarsier Pharma, Ltd., a clinical-stage ophthalmic biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted a Special Protocol Assessment (SPA) for the Tarsier-04 Phase 3 trial evaluating TRS01 eye drops for non-infectious uveitis, including uveitic glaucoma. This SPA confirms FDA agreement with the study design, supporting potential future marketing applications.

In September 2024, Proviant Therapeutics enrolled the first patients in CLARITY, a global Phase 3 study evaluating brepocitinib, a dual selective TYK2/JAK1 inhibitor, in non-anterior non-infectious uveitis. The FDA also granted Fast Track Designation for brepocitinib, highlighting its potential as a first-in-class oral therapy.

Several local therapies are advancing as well. IL-6 inhibitors such as vamikibart (Genentech/Roche) are being studied in ongoing MEERKAT and SANDCAT Phase 3 trials, while trispecific antibodies such as SZN-8143 (Surrozen) and KSI-101 (Kodiak Sciences) are being evaluated for targeted ocular inflammation, demonstrating promising safety and efficacy results. These developments collectively underscore significant growth potential in the global uveitis treatment market.

Category-wise Analysis

By Drug Class Insights

Corticosteroids are expected to capture a 31.5% share of the global uveitis treatment market by 2026. They remain the conventional first-line therapy for non-infectious uveitis, administered topically, regionally, or systemically. Regional corticosteroid options, such as intravitreal triamcinolone acetonide, are increasingly preferred. According to a survey published in Journal of Ophthalmic Inflammation and Infection (2024), 54.7% of participants with unilateral uveitis favored regional corticosteroids as their first-line treatment, reflecting widespread acceptance and driving market growth.

By Indication Insights

Anterior uveitis is projected to hold nearly 57.8% of the global uveitis treatment market by 2026. This form primarily affects the iris and ciliary body and accounts for 70%–90% of all uveitis cases (American Academy of Ophthalmology, 2024). The high prevalence is compounded by associations with autoimmune disorders such as ankylosing spondylitis and sarcoidosis. Early diagnosis and targeted management reduce the risk of complications including cataracts and glaucoma, increasing demand for effective therapies. Advanced corticosteroid and biologic options are further driving segment growth.

By Disease Etiology Insights

Non-infectious uveitis is estimated to hold nearly 74.8% of the global uveitis treatment market by 2026. While infectious uveitis remains prevalent worldwide, viral infections account for 56.1% of cases, followed by Toxoplasma gondii infections (24.5%). Infection of the retinal pigment epithelium (RPE) induces growth factors such as VEGF and thrombospondin-1, worsening retinal damage. The high global prevalence of non-infectious uveitis, often linked to autoimmune conditions, drives demand for safe and effective corticosteroid and biologic therapies, sustaining market growth.

Regional Insights

North America Uveitis Treatment Market Trends

North America is projected to capture 34.7% of the global uveitis treatment market by 2026, driven by high disease prevalence, advanced healthcare infrastructure, and growing awareness of eye disorders.

According to the American Academy of Ophthalmology (AAO) 2024 report, uveitis accounts for 10% of blindness in the United States, with a prevalence of 58–121 cases per 100,000 persons. Further, the Centers for Disease Control and Prevention (CDC) 2022 estimates indicate over 3.4 million Americans aged 40 or older are blind or visually impaired, while up to 21 million experience vision difficulties, highlighting significant unmet needs in ocular care.

Supporting the growing market, in October 2021, Fresenius Kabi introduced Idacio, a biosimilar to injectable adalimumab, in Canada. It is prescribed for pediatric chronic noninfectious anterior uveitis and adult noninfectious uveitis, offering improved access to effective treatment.

Innovation continues to strengthen North America’s uveitis treatment market. In September 2025, promising Phase 1b results for KSI-101 showed rapid retinal drying and improved visual acuity in macular edema secondary to inflammation. Likewise, October 2025 Phase III data for vamikibart demonstrated meaningful vision gains in uveitic macular edema. Together with rising disease awareness and strong healthcare infrastructure, these advancements are accelerating market growth.

Europe Uveitis Treatment Market Trends

Europe is projected to account for 28.8% of the global uveitis treatment market by 2026, driven by rising government support, awareness initiatives, and increasing access to advanced therapies. National Health Service (NHS) England has issued guidance for 2023–2024, emphasizing standardized integrated care pathways across cataract, urgent eye care, medical retina, and glaucoma services, aiming to improve equity, reduce patient backlogs, and enhance overall eye care delivery. Such policy support strengthens the adoption of advanced uveitis therapies across the region.

Biosimilars and sustained-release corticosteroid implants are also key contributors to market growth. In June 2024, ANI Pharmaceuticals announced a definitive agreement to acquire Alimera Sciences, a company focused on vision-preserving treatments. Alimera’s ILUVIEN (fluocinolone acetonide intravitreal implant 0.19mg) treats diabetic macular edema (DME) in the U.S., Europe, and the Middle East, and non-infectious posterior uveitis (NIU-PS) in Europe and the Middle East, while YUTIQ is indicated for chronic NIU-PS in the U.S. only.

Further supporting the market, in March 2025, Iluvien received FDA approval for chronic non-infectious posterior uveitis, based on Phase 3 trials (ClinicalTrials.gov Identifiers: NTC01694186 and NTC02746991) demonstrating efficacy and sustained delivery over 36 months. These approvals and ongoing adoption of advanced therapies continue to drive growth in Europe’s uveitis treatment market.

Asia Pacific Uveitis Treatment Market Trends

The Asia Pacific market is rapidly expanding, projected to grow at a CAGR of 9.1% over the forecast period, driven by increasing prevalence of inflammatory eye diseases, rising healthcare awareness, and the introduction of innovative therapies. Suprachoroidal injection-based corticosteroid therapies, offering targeted drug delivery with reduced side effects, are fueling growth in the region.

In November 2024, Japanese firm Santen Pharmaceutical Co., Ltd. and China-based biotech Arctic Vision signed a commercial collaboration agreement for ARVN001. ARVN001 is a triamcinolone acetonide suprachoroidal injectable suspension with the patented SCS Microinjector® technology, for the treatment of uveitic macular edema (UME) in China (excluding Taiwan, Hong Kong, and Macau). ARVN001, already FDA-approved in the U.S. as XIPERE®, is the first suprachoroidal therapy for UME and showed positive Phase III results in China by July 2024, offering sustained efficacy and reduced impact on healthy ocular tissue.

Further expansion is supported by regulatory approvals across the region. In January 2025, the Therapeutic Goods Administration (TGA) of Australia formally approved ARCATUS® (ARVN001) for UME, following prior approvals in the U.S. and Singapore. Additionally, in February 2025, the China National Medical Products Administration (NMPA) accepted the NDA for ARCATUS, backed by successful Phase III clinical data. These developments highlight growing access to advanced, safe, and effective therapies, propelling market growth in Asia Pacific.

Competitive Landscape

The global uveitis treatment market is highly competitive, with players actively pursuing strategic initiatives such as innovative drug development, mergers and acquisitions, and regional expansion. Continuous R&D, introduction of advanced therapies, and focus on improving patient access are intensifying competition and driving rapid market evolution.

Key Industry Developments:

• In September 2025, Kodiak Sciences presented Phase 1b APEX study results for KSI-101, a bispecific antibody targeting IL-6 and VEGF, showing meaningful improvements in best-corrected visual acuity (BCVA) and rapid retinal drying in macular edema secondary to inflammation (MESI).
• In October 2025, Genentech reported Phase III results for vamikibart in uveitic macular edema (UME), demonstrating rapid vision improvements and reduced macular thickness compared to a sham procedure, highlighting the therapy’s potential to treat inflammation-driven retinal fluid accumulation effectively.

Companies Covered in Uveitis Treatment Market

• Novartis AG
• Bausch & Lomb Incorporated
• AbbVie Inc.
• Fresenius Kabi AG
• Santen Pharmaceutical Co., Ltd.
• Genentech, Inc.
• KODIAK SCIENCES INC.
• ARCTIC VISION HONG KONG BIOTECH LIMITED
• Surrozen
• Tarsier® Pharma
• EyePoint Pharmaceuticals
• ANI Pharmaceuticals, Inc.